1. Introduction {#s0005}
===============

One of the major complications associated with allogeneic hematopoietic stem cell transplantation (alloHSCT) is the high incidence of acute graft-versus-host disease (GvHD) caused by donor T-lymphocytes. Depletion of donor T-lymphocytes is a well-established therapeutic option for GvHD-prophylaxis. Recently, we showed a sustained depletion of conventional and regulatory CD4 T cells in patients treated with ATG-Genzyme^™^ (Thymoglobulin^®^, ATG-G) [@bib1], a polyclonal antibody preparation containing a broad spectrum of antibodies directed against T cells [@bib2] and potentially thymic stromal cells. Interestingly, total CD8 T cell counts were similar in ATG-G treated and untreated patients[@bib1]. In principle, T cell recovery after transplantation can take place through thymus dependent regeneration as well as by proliferation of existing T cells [@bib3].

Here, we addressed whether the rapid CD8 T cell recovery after ATG-G depletion resulted from accelerated CD8 T cell regeneration or increased peripheral CD8 T cell proliferation and in how far this influenced GvHD incidence. Therefore, we studied the distribution of different CD8 T cell subsets and their proliferative capacity in ATG-G treated patients of the same patient cohort.

2. Material and methods {#s0010}
=======================

A detailed description of methods and patient cohorts can be found in Na et al. [@bib1] (approval by the Charité -- Berlin local ethics committee no. EA4/128/09). Briefly, we compared CD8 T cell reconstitution in 12 alloHSCT patients receiving ATG-G according to standard procedure protocols (ATG-G group, for *d*+180: *n*=11) with 8 alloHSCT patients not receiving ATG-G (noATG-G group, for *d*+180: *n*=3). Patient characteristics and clinical outcome are presented in [Table 1](#t0005){ref-type="table"}. Indications for transplantation were hematologic malignancies in all cases (AML *n*=17, ALL *n*=2, CLL *n*=1). Patients received ATG-G additionally to standard conditioning regimens if transplanted with grafts from matched-unrelated donors (MUD) as opposed to matched related donors (MRD) in the noATG-G group. One patient receiving an MUD graft did not receive ATG-G.

Multicolor flow cytometry (Becton Dickinson LSRII supported by FlowJo 9.3 software, TreeStar) was used to identify different CD8 T cell subsets after standard staining procedures of peripheral blood mononuclear cells (PBMC) from fresh heparinized blood samples. The following antibodies were used to characterize the CD8 T cell subsets: anti-CD3 APC/Cy7 (clone UCHT1; BioLegend), anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend), anti-CD8 V500 (clone RPA-T8; BD Biosciences), anti-CD45RA PerCP/Cy5.5 (clone HI100; BioLegend), anti-CD45RO Pacific Blue (clone UCHL1; BioLegend), and anti-CD197 (CCR7) Alexa Fluor 488 (clone TG8/CCR7; BioLegend). For evaluation of Ki67 expression stainings were performed using anti-CD3 APC/Cy7 (clone UCHT1; BioLegend), anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend), anti-CD8 V500 (clone RPA-T8; BD Horizon), anti-CD45RA eFlour605 (clone HI100; eBioscience) and anti-Ki67 FITC (clone B56, BD Pharmingen). CD3 T cell counts were obtained by staining whole blood samples with CD3-Cy5 (clone UCTH-1, DRFZ, Berlin) and using BD TruCount^TM^ controls (BD Biosciences). For group comparisons the Mann-Whitney-U test was used (GraphPad Software, La Jolla, CA).

3. Results {#s0015}
==========

Analysis of the CD3 T cell compartment revealed comparable cell counts in both groups except day 15 after transplantation with significantly lower absolute counts in the ATG-G group ([Fig. 1](#f0005){ref-type="fig"}A; 46.29 cells/μl±11.61 (SEM) versus 365.1 cells/μl±102.8 (SEM), *p*\<0.005). The share of CD8^+^ T cells was significantly higher in the ATG-G group at all time points post transplantation except *d*+180 ([Fig. 1](#f0005){ref-type="fig"}B). On day 15 we observed high rates of CD8 T cell proliferation only in the ATG-G group, as shown by Ki67 staining ([Fig. 1](#f0005){ref-type="fig"}C,D; 49.0%±6.8% in ATG-G group versus 11.0%±2.6% in noATG-G group on *d*+15, *p*\<0.01). We then compared proliferative activity of CD45RA^+^ and CD45RA^−^ CD8 T cells within the ATG-G group. Proliferation rates of CD45RA^−^ CD8 T cell subsets were higher at all time points after transplantation as compared to CD45RA^+^ CD8 T cell subsets with significant differences on days 60, 90 and 180 ([Fig. 1](#f0005){ref-type="fig"}E,F). At day 15 CD45RA^+^ CD8 T cells also showed a strikingly high proportion of Ki67^+^ cells (35.1%±7.7%). However, at day 30 this share dropped (3.2%±0.9%) and remained low.

Next, we used a gating strategy originally suggested by Sallusto et al. [@bib4] to assess naive (CD45RA^+^CCR7^+^), central memory (CM, CD45RA^−^CCR7^+^), effector memory (EM, CD45RA^−^CCR7^−^) and effector (CD45RA^+^CCR7^−^) CD8 T cells ([Fig. 2](#f0010){ref-type="fig"}A). We observed significantly higher frequencies of EM CD8 T cells in the ATG-G group at all time points except *d*+180 ([Fig. 2](#f0010){ref-type="fig"}B). In contrast, frequencies of naive CD8 T cells were significantly lower in ATG-G treated patients compared to patients without ATG-G treatment at all time points post transplantation ([Fig. 2](#f0010){ref-type="fig"}C). The frequencies of CM and effector CD8 T cells were comparable in both groups ([Fig. 2](#f0010){ref-type="fig"}D, E).

4. Discussion {#s0020}
=============

Investigating the impact of ATG-G as a T cell depleting strategy [@bib2], as expected we observed lower CD3 T cell counts in the ATG-G group. Considering the half-life of ATG-G (clearance to sub-therapeutic levels by a median of 17±9 days [@bib5]), unsurprisingly there was only a significant difference of CD3 T cell counts early after alloHSCT. The observed persistent increase of CD8 T cell frequencies is likely to be mainly due to decreased CD4 T cell counts as previously described [@bib1].

Analysis of the CD8 T cell compartment in detail revealed a shift towards high EM and low naive CD8 T cell frequencies in the ATG-G group. This shift was observed up to *d*+180 after alloHSCT, suggesting indirect long-term effects resulting from ATG-G treatment. Low shares of naive CD8 T cells could be the consequence of a rapid transition into the memory pool or thymic impairment due to ATG-G as previously suggested for CD4 T cell regeneration [@bib1]. The rapid increase of EM CD8 T cells appears to be driven mainly by homeostatic mechanisms in the ATG-G depleted host, since concomitant high rates of CD8 T cell proliferation were found around day 15 in the ATG-G group only. This hypothesis is supported by consistently higher proliferation rates of CD45RA^−^ CD8 T cells as compared to CD45RA^+^ CD8 T cells within the ATG-G group. However, it has previously been shown that changes towards an EM phenotype from other subsets such as naive CD8 T cells are also induced by T cell receptor stimulation and that CM CD8 T cells undergo various phenotypic changes upon cytokine stimulation, amongst others towards an EM phenotype [@bib6]. It cannot be excluded that both these mechanisms contribute to the expansion of the EM CD8 T cell subset. Yet, the same reports also support the notion that EM CD8 T cells are especially receptive to cytokine stimulation [@bib6] thus favoring the hypothesis of homeostatic proliferation.

In line with larger clinical studies demonstrating ATG-G efficacy especially for prevention of severe acute GvHD (reviewed in [@bib7]), acute GvHD-rates in both patient groups in our study were similar even though ATG-G treated patients were transplanted with MUD grafts as opposed to MRD grafts in the noATG-G group and thus were at higher risk of GvHD (acute GvHD ATG-G group versus noATG-G group: Grade I and II 58% versus 63%, Grade III and IV 17% versus 13%). Consequently, the initial T cell depletion by ATG-G limited GvHD in MUD transplantations as intended. Yet, this also suggests that the significant expansion of EM CD8 T cells in the ATG-G group is not driving GvHD. Results from mouse studies equally suggest that memory CD8 T cells are less potent in mediating acute GvHD than naive CD8 T cells [@bib8]. EM CD8 T cells appear to be favorable over CM CD8 T cells in this respect in mice [@bib9; @bib10]. Likewise, *in vitro* studies with human material from healthy donors indicate an increased alloreactivity of naive CD8 T cells as compared to memory CD8 T cells under certain conditions [@bib11].

In summary, our data suggest that rapid recovery of CD8 T cells after ATG-G induced T cell depletion in alloHSCT patients is due to peripheral homeostatic proliferation of EM CD8 T cells and not due to accelerated regeneration of naive CD8 T cells. This leads to a characteristic shift to EM CD8 T cells that is not associated with higher rates of GvHD.
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![Proliferative capacity of CD8 T cells after alloHSCT. Mean values of (A) CD3 T cell counts (cells/μl±standard error of mean (SEM)) and (B) CD8 T cell frequencies (%±SEM) are shown. Proliferation of total (C, D) and CD45RA^+^ and RA- (E, F; ATG-G group only) CD8 T cells was measured by Ki67 analysis. For statistical evaluation the Mann Whitney U test was used. ^⁎^*p*\<0.05; ^⁎⁎^*p*\<0.01; ^⁎⁎⁎^*p*\<0.005.](gr1){#f0005}

![Reconstitution of CD8 T cell subsets after alloHSCT. (A) Gating strategy according to Sallusto et al. (B--E) Frequencies of CD8 T cell subsets in ATG and noATG groups. Mean values of frequencies (%±SEM) are shown. For statistical evaluation the Mann Whitney U test was used. ^⁎^*p*\<0.05; ^⁎⁎^*p*\<0.01; ^⁎⁎⁎^*p*\<0.005.](gr2){#f0010}

###### 

Patient characteristics and clinical outcome.

                                                                    *Patient no.*   *Age*[a](#tbl1fna){ref-type="table-fn"}(years)   *Diagnosis*   *Donor*            *Conditioning regimen*   *Deceased*[b](#tbl1fnb){ref-type="table-fn"}   *Leukocyte engraftment*[c](#tbl1fnc){ref-type="table-fn"}   *Grade of aGVHD*
  ----------------------------------------------------------------- --------------- ------------------------------------------------ ------------- ------------------ ------------------------ ---------------------------------------------- ----------------------------------------------------------- ------------------
  **ATG-G group**                                                   1               50                                               AML           MUD                Cy/TBI                                                                  *d*+15                                                      I
  2 *mg*/*kg*/*day on days −*3,*−*2,*−*1 *before transplantation*   2               27                                               AML           MUD                Cy/TBI                                                                  *d*+18                                                      III
  3                                                                 28              ALL                                              MUD           Cy/TBI                                      *d*+15                                         I                                                           
  4                                                                 48              AML                                              MUD           Cy/TBI             x                        d+12                                           I                                                           
  5                                                                 57              ALL                                              MUD           Cy/TBI                                      *d*+13                                         III                                                         
  6                                                                 58              AML                                              MUD           Fludara/Treo                                *d*+16                                         I                                                           
  7                                                                 50              AML                                              MUD           Cy/TBI                                      *d*+14                                         None                                                        
  8                                                                 69              AML                                              MUD           FLAMSA                                      *d*+13                                         II                                                          
  9                                                                 60              AML                                              MUD           Fludara/Treo                                *d*+16                                         I                                                           
  10                                                                47              AML                                              MUD           Cy/TBI                                      *d*+13                                         None                                                        
  11                                                                57              AML                                              MUD           Fludara/8 Gy TBI                            *d*+17                                         None                                                        
  12                                                                48              AML                                              MUD           Cy/TBI                                      *d*+13                                         I                                                           
                                                                                                                                                                                                                                                                                                          
  **noATG-G group**                                                 13              58                                               AML           MRD                Fludara/Treo                                                            *d*+15                                                      II
  14                                                                41              AML                                              MRD           FLAMSA             x                        *d*+8                                          None                                                        
  15                                                                34              AML                                              MRD           Cy/TBI             x                        *d*+17                                         None                                                        
  16                                                                57              AML                                              MRD           Cy/TBI             x                        *d*+15                                         II                                                          
  17                                                                40              AML                                              MUD           Bu/Cy              x                        *d*+30                                         III                                                         
  18                                                                61              AML                                              MRD           MitoFLAG           x                        *d*+17                                         I                                                           
  19                                                                57              AML                                              MRD           Fludara/Treo                                *d*+19                                         II                                                          
  20                                                                67              CLL                                              MRD           Fludara/2 Gy TBI                            *d*+17                                         II                                                          

Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphatic leukemia; Bu, busulfane; CLL, chronic lymphatic leukemia; Cy, cyclophosphamide; FLAMSA, Fludarabin, Cytosin-Arabinosid and Amsacrin; Fludara, fludarabine; aGvHD, acute graft-versus-host disease; Gy, Gray; MitoFLAG, Mitoxantrone, Fludarabine, Cytosin-Arabinosid and granulocyte-colony stimulating factor; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation; Treo, treosulfane.

Age at transplantation.

Deceased between days +90 and +180 after transplantation.

Time to leukocyte engraftment in days after transplantation.
